SCHEMBL390305

SCHEMBL390305

CC(C)CC(=O)OCOC(=O)N(CC(=O)OCc1ccccc1)C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC15A1 P46059 2/20 0.43
ALDH1A1 P00352 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MAPK1 P28482 1/20 0.41
ABCB1 P08183 2/20 0.41
GLA P06280 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
MMP9 P14780 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CTSS P25774 1/20 0.36
CDC25B P30305 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL393231 0.89 ALDH1A1 (0.42) SLC15A1ALDH1A1L3MBTL1MAPK1ABCB1
SCHEMBL389298 0.86 ALDH1A1 (0.44) SLC15A1ALDH1A1L3MBTL1MAPK1ABCB1
SCHEMBL393102 0.86 ALDH1A1 (0.59) ALDH1A1L3MBTL1MAPK1SMN1; SMN2MEN1
SCHEMBL395208 0.86 ALDH1A1 (0.44) ALDH1A1L3MBTL1MAPK1SMN1; SMN2MEN1
SCHEMBL394986 0.85 ALDH1A1 (0.43) SLC15A1ALDH1A1L3MBTL1MAPK1SMN1; SMN2
SCHEMBL393477 0.85 ALDH1A1 (0.43) ALDH1A1L3MBTL1MAPK1SMN1; SMN2MEN1
SCHEMBL393704 0.85 ALDH1A1 (0.40) ALDH1A1L3MBTL1MAPK1SMN1; SMN2MMP9
SCHEMBL393317 0.82 ALDH1A1 (0.40) ALDH1A1L3MBTL1MAPK1SMN1; SMN2MEN1
SCHEMBL394992 0.82 ALDH1A1 (0.41) ALDH1A1L3MBTL1MAPK1SMN1; SMN2MEN1
SCHEMBL390082 0.81 ALDH1A1 (0.40) ALDH1A1L3MBTL1MAPK1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919879-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES Wyeth a Corporation of the State of Delaware (US) 2008-05-14 EP claimed
WO-2007027599-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES WYETH (US) 2007-03-08 WO claimed
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines WYETH (US) 2007-03-01 US claimed
US-8101590-B2 9-aminocarbonylsubstituted derivatives of glycylcyclines WYETH LLC (US) 2012-01-24 US disclosed
EP-1919879-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES Wyeth a Corporation of the State of Delaware (US) 2008-05-14 EP disclosed
WO-2007027599-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES WYETH (US) 2007-03-08 WO disclosed
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines WYETH (US) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines Q6ZSR9, GMPS, RPS10 SLC15A1 2528/4885ALDH1A1 1826/4885L3MBTL1 3336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.